Dealing with frequent hitters in drug discovery: a multidisciplinary view on the issue of filtering compounds on biological screenings

dc.creatorDantas, Rafael Ferreira
dc.creatorEvangelista, Tereza Cristina Santos
dc.creatorNeves, Bruno Junior
dc.creatorSenger, Mário Roberto
dc.creatorAndrade, Carolina Horta
dc.creatorFerreira, Sabrina Baptista
dc.creatorSilva Junior, Floriano Paes
dc.date.accessioned2024-09-12T13:57:44Z
dc.date.available2024-09-12T13:57:44Z
dc.date.issued2019
dc.description.abstractIntroduction: The timely identification biologically active chemicals, in disease relevant screening assays, is a major endeavor in drug discovery. The existence of frequent hitters (FHs) in non-related assays poses a formidable challenge in terms of whether to consider these molecules as chemical gold or promiscuous non-selective reactive trash (also known as PAINS – pan assay interference compounds). Areas covered: In this review, the authors bring together expertize in synthetic chemistry, cheminformatics and biochemistry, three key areas for dealing with FHs. They discuss synthetic methods facilitating preparation of chemically diverse molecular libraries, while favoring activity in the biological space. They also survey and discuss recent computational advances in the prediction of PAINS from chemical structures. Finally, they review experimental approaches for the validation of the biological activity of screening hits and discuss alternatives for exploiting promiscuity and chemical reactivity. Expert opinion: It’s essential to develop more efficient computational methods to reliably recognize PAINS in distinct molecular environments. Accordingly, advances in synthetic chemistry hold the promise to provide a better quality of chemical matter for drug discovery. Medicinal chemists should be more open to screening for hits showing biologically complex mechanisms of action rather than discarding molecules that may prove valuable as innovative disease treatments.
dc.identifier.citationDANTAS, Rafael Ferreira et al. Dealing with frequent hitters in drug discovery: a multidisciplinary view on the issue of filtering compounds on biological screenings. Expert Opinion on Drug Discovery, London, v. 14, n. 12, p. 1269-1282, 2019. DOI: 10.1080/17460441.2019.1654453. Disponível em: https://www.tandfonline.com/doi/full/10.1080/17460441.2019.1654453. Acesso em: 10 set. 2024.
dc.identifier.doi10.1080/17460441.2019.1654453
dc.identifier.issn1746-0441
dc.identifier.issne- 1746-045X
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/17460441.2019.1654453
dc.language.isoeng
dc.publisher.countryGra-bretanha
dc.publisher.departmentFaculdade de Farmácia - FF (RMG)
dc.rightsAcesso Restrito
dc.subjectChemical biology
dc.subjectCheminformatics
dc.subjectMulti-target
dc.subjectPAINS
dc.subjectPolypharmacology
dc.subjectPrivileged scaffolds
dc.titleDealing with frequent hitters in drug discovery: a multidisciplinary view on the issue of filtering compounds on biological screenings
dc.typeArtigo

Arquivos

Licença do Pacote

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: